In Ethiopian adults with P vivax malaria (162 analysed), day-28 ACPR was 98.7% with chloroquine + low-dose primaquine and 98.8% with pyronaridine-artesunate + low-dose primaquine; no serious adverse events. Substudy: only the latter fully blocked mosquito infection by day 1.
RCTn = 176
Bezabih et al. Efficacy of chloroquine plus low-dose primaquine and pyronaridine-artesunate plus low-dose primaquine against Plasmodium vivax malaria in adults and transmission to mosquitoes in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial